Primary chemoprophylaxis for tuberculosis in HIV-infected patients;Chimioprophylaxie primaire de la tuberculose chez les personnes infectees par le VIH dans les pays non industrialises

Cahiers Sante

Volumn 7, Issue 2, 1997, Pages 89-94

  Anglaret, Xavier ^a   Dabis, François ^b   Batungwanayo, Jean ^c   Perronne, Christian ^d   Taelman, Henri ^e   Bonard, Dominique ^a   Sylla Koko, Fatoumata ^a   Leroy, Valériane ^b   Van De Perre, Philippe ^f   Vildé, Jean Louis ^g   Salamon, Roger ^b  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE TREICHVILLE   (Côte d’Ivoire)

^b INSERM   (France)

^c Centre Hospitalier Universitaire de Kigali   (Rwanda)

^d Serv Maladies Infectieuses T   (France)

^e UNIVERSITY OF NAIROBI   (Kenya)

^f CENTRE MURAZ   (Burkina Faso)

^g BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ISONIAZID;

AFRICA; ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL TRIAL; DEVELOPING COUNTRY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MYCOBACTERIUM TUBERCULOSIS; PROPHYLAXIS; TUBERCULOSIS;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTITUBERCULAR AGENTS; CENTERS FOR DISEASE CONTROL AND PREVENTION (U.S.); CHEMOPREVENTION; CLINICAL TRIALS; COST-BENEFIT ANALYSIS; DEVELOPED COUNTRIES; DEVELOPING COUNTRIES; DRUG RESISTANCE, MICROBIAL; HAITI; HUMANS; INCIDENCE; ISONIAZID; MYCOBACTERIUM TUBERCULOSIS; PATIENT COMPLIANCE; PLACEBOS; PRACTICE GUIDELINES; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; TUBERCULIN TEST; TUBERCULOSIS, PULMONARY; UGANDA; UNITED STATES; WORLD HEALTH ORGANIZATION; ZAMBIA;

EID: 12644292882     PISSN: 11575999     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Raviglione M, Snider D, Kochi A. Global epidemiology of tuberculosis. JAMA 1995 ; 273 : 220-6.
2. O'Brien R, Perriëns J. Preventive therapy for tuberculosis in HIV infection : the promise and the reality. AIDS 1995 ; 9 : 665-73.
3. Grosset J. Present status of chemotherapy for tuberculosis. Rev Infect Dis 1989 ; 11 (suppl. 2) : S347-52.
4. Guelar A, Gatell J, Verdejo J, et al. A prospective study ot the risk of tuberculosis among HIV-infected patients. AIDS 1993 ; 7 : 1345-9.
5. Selwyn P, Hartel D, Lewis V, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med 1989 ; 320 : 545-50.
6. Centers for Disease Control. Diagnosis and management of mycobacterial infection and disease in persons with human T-lymphocytotropic virus type III/lymphadenopathy-associated virus infection. Morb Mortal Wkly Rep 1986 ; 35 : 448-52.
7. Moreno S, Baraia-Etxaburu J, Bouza E, et al. Risk for developping tuberculosis among anergic patients infected with HIV. Ann Intern Med 1993 ; 119 : 194-8.
8. Centers for Disease Control. Purified protein derivative (PPD)-tuberculin anergy and HIV infection : guidelines for anergy testing and management of anergic persons at risk of tuberculosis. Morb Mortal Wkly Rep 1991 ; 40 (suppl. 55-5) : 27-33.
9. World Health Organization, International Union Against Tuberculosis and Lung Disease. Tuberculosis preventive therapy in HIV-infected individuals. Wkly Epidem Rec 1993 ; 49 : 361-4.
10. Halsey N, Coberly J, Atkinson J, et al. Twice weekly isoniazide for tuberculose prophylaxis. In : Programme and abstracts of the 10th International Conference on AIDS. Yokohama, Japan, 1994 : 167 (abstract no PB-0681).
11. Lecceur H, Truffot-Pernot C, Grosset J. Experimental short course preventive therapy of tuberculosis with rifampicin and pyrazinamide. Am Rev Respir Dis 1989 , 140 : 1189-93.
12. Allen S, Batungwanayo J, Kerlikowske K, et al Two-year incidence of tuberculosis in cohorts of HIV-infected and uninfected urban Rwandan women. Am J Med 1992 ; 146 : 1439-44.
13. Mukadi Y, Perriëns J, St Louis M, et al. Spectrum of immunodeficiency in HIV-1-infected patients with pulmonary tuberculosis in Zaïre. Lancet 1993 ; 342 : 143-6.
14. Whalen C, Horsburgh C, Horn D, Lahart C, Simberkoff M, Ellner J. Accelerated course of human immunodeficiency virus infection after tuberculosis. J Respir Crit Care Med 1995 ; 151 : 129-35.
15. Schulzer M, Fitzgerald J, Enarson D, Grzybowski S. An estimate of the future size of the tuberculosis problem in sub-saharan Africa resulting from the HIV-infection. Tuberc Lung Dis 1992 ; 73 : 52-8.
16. Grzybowski S. Preventive treatment for tuberculosis control in developping countries. The case for preventive chemotherapy. Bull Intern Union Tuberc Lung Dis Suppl 1990/1991 ; 66 : S25.
17. Styblo K. Preventive chemotherapy for tuberculosis control in developing countries : the case against preventive chemotherapy. Bull Intern Union Tuberc Lung Dis Suppl 1990/1991 ; 66 : S27-8.
18. Porter J, Mc Adam K. Aspect of tuberculosis in Africa in the AIDS era - the role of chemoprophylaxis. Trans Roy Soc Trop Med Hyg 1992; 86: 467-9.
19. Reeve P. Tuberculosis and HIV infection. Lancet 1993 ; 342 : 676.
20. Godfrey-Faussett P, Mwinga A, Raviglione M, et al. Tuberculosis and HIV infection. Lancet 1993 ; 342 : 1368.
21. Lange J. HIV-related morbidity and mortality in sub-saharan Africa : opportunities for prevention. AIDS 1993 ; 7 : 1675-6.
22. Anglaret X, Taelman H, Ladner J, Batungwanayo J, Dabis F. Tuberculosis and chemoprophylaxis in Africa. Lancet 1995 ; 345 : 867-8.
23. De Cock K, Grant A, Porter J. Preventive therapy for tuberculosis in HIV-infected persons : international recommandations, research, and practise. Lancet 1995 ; 345 : 756-63.
24. Walley J, Porter J. Chemoprophylaxis in tuberculosis and HIV infection. Br Med J 1995 ; 310 : 1621-2.
25. Pape J, Jean S, Ho J, Hafner A, Johnson W. Effect of izoniazide prophylaxis on incidence of active tuberculosis and progression of HIV infection. Lancet 1993 ; 342 : 268-72.
26. Wadhawan D, Hira S, Mwansa N, et al. Preventive tuberculosis chemotherapy with isoniazid among persons infected with HIV-1. In : Programme and abstracts of the 9th international conference on AIDS. Berlin, Germany, 1993: 321 (PO-B07-1114).
27. Nsubuga P, Vjecha M, Whalen C, et al. Preventive therapy for tuberculosis in HIV-infected Ugandans. In : Programme and abstracts of the IXth international conference on AIDS and STD in Africa. Kampala, Uganda, 1995 : 95 (Mo-B010).
28. Twumasi P. Preventive therapy for tuberculosis. Lancet 1995 ; 345 : 1439.
29. Nolan C, Aitken M, Elarth A, Anderson K, Miller W. Active tuberculosis after isomazid chemoprophylaxis of southeast Asian refugees. Am Rev Respir Dis 1986 ; 133 : 431-6.
30. Aisu T, Raviglione M, Van Praag E, et al. Preventive chemotherapy for HIV-associated tuberculosis in Ouganda : a feasability study. In : Programme and abstracts of the 9th international conference on AIDS. Berlin, Germany, 1993 : 52 (WS-BO9-3).
31. Godfrey-Faussett P, Baggaley R, Mwinga A, et al. Recruitment to a trial of tuberculosis preventive therapy from a voluntary HIV testing centre in Lusaka: relevance to implementation. Trans Roy Soc Trop Med Hyg 1995 ; 89 : 354-8.
32. Elliot A, Halwiindi B, Hayes R, et al. The impact of human immunodeficiency virus on presentation and diagnosis of tuberculosis in a cohort study in Zambia. J Trop Med Hyg 1993 ; 96 : 1-11.
33. Duncan L, Elliott A, Hayes R, et al. Tuberculin sensitivity and HIV-1 status of patients attending a sexually transmitted diseases clinic in Lusaka, Zambia : a cross-sectional study. Trans Roy Soc Trop Med Hyg 1995 ; 89 : 37-40.
34. Coberly J, Halsey N, Johnson M, et al. Acceptability of twice weekly short course rifampicin and pyrazinamide for tuberculose preventive therapy in HIV-infected adults. In : Programme and abstracts of the 9th international conference on AIDS. Berlin, Germany, 1993: 328 (Po-B07-1158).
35. Grosset J. Treatment of tuberculosis in HIV infection. Tuberc Lung Dis 1992 , 1992 : 378-83.
36. Pozniak A, MacLeod G, Mahari M, Legg W, Weinberg J. The influence of HIV status on single and multiple drug reactions to antituberculosis therapy in Africa. AIDS 1992 ; 6 : 809-14.
37. Heymann SJ. Modelling the efficacy of prophylactic and curative therapies for preventing the spread of tuberculosis in Africa. Trans Roy Soc Trop Med Hyg 1993 ; 87 : 406-11.
38. Foster S. When does tuberculose preventive therapy make sense? A model of economic costs and benefits In : Programme and abstracts of the IXth international conference on AIDS and STD in Africa. Kampala, Uganda, 1995 : 95 (Mo-B011).